A large pharmacy claims-based descriptive analysis of patients with migraine and associated pharmacologic treatment patterns

David J Muzina, William Chen, Steven J BowlinMedco Health Solutions Inc and Medco Research Institute, LLC, Franklin Lakes, NJ, USAPurpose: To investigate drug use, prescribing patterns, and comorbidities among patients with migraine in a large pharmacy claims database.Methods: 104,625 migraine subje...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Muzina DJ, Chen W, Bowlin SJ
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2011
Materias:	Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
Acceso en línea:	https://doaj.org/article/a54c52379da94ed3b3ab73c79ca3db64
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:a54c52379da94ed3b3ab73c79ca3db64
record_format	dspace
spelling	oai:doaj.org-article:a54c52379da94ed3b3ab73c79ca3db642021-12-02T07:01:06ZA large pharmacy claims-based descriptive analysis of patients with migraine and associated pharmacologic treatment patterns1176-63281178-2021https://doaj.org/article/a54c52379da94ed3b3ab73c79ca3db642011-11-01T00:00:00Zhttp://www.dovepress.com/a-large-pharmacy-claims-based-descriptive-analysis-of-patients-with-mi-a8645https://doaj.org/toc/1176-6328https://doaj.org/toc/1178-2021David J Muzina, William Chen, Steven J BowlinMedco Health Solutions Inc and Medco Research Institute, LLC, Franklin Lakes, NJ, USAPurpose: To investigate drug use, prescribing patterns, and comorbidities among patients with migraine in a large pharmacy claims database.Methods: 104,625 migraine subjects (identified according to the criteria in the International Classification of Diseases, Ninth Revision [ICD-9] for migraine or migraine-specific acute medication use) and an equal number of control patients were selected from a de-identified claims database; the prevalence of patients with migraine-specific claims was determined. Patient demographics, migraine-related medication use, other psychotropic medication use, and comorbidities over a 12-month period were compared between the migraine population and the control group and between migraine subgroups.Results: Of the study population, 3.5% had a migraine diagnosis according to the ICD-9 or received a migraine-specific acute medication. Compared with controls, migraine patients had significantly greater disease comorbidity and higher use of prescription nonsteroidal anti-inflammatory drugs and controlled painkillers; they were also more likely to receive medications used to prevent migraines and other nonmigraine psychotropic medications, such as anxiolytics and hypnotics. Among migraine patients, 66% received acute migraine-specific medication while only 20% received US Food and Drug Administration&ndash;approved migraine preventive therapy. Notably, one-third of high triptan users did not receive any kind of preventive medication. Multiple medical and psychiatric comorbidities were observed at higher rates among migraine sufferers. In addition to significantly higher utilization of antidepressants compared with controls, migraine patients also received significantly more other psychotropic drugs by a factor of 2:1.Conclusion: Acute migraine medications are commonly used and frequently dispensed at rates that raise concern of overuse; high use is often seen without any preventive medications. Furthermore, use of US Food and Drug Administration&ndash;approved preventive medications is low. Finally, patients with migraine are significantly more likely to receive other psychotropic medications. These findings suggest efforts to optimize the management of migraines could address appropriate use of triptans, increased and more effective use of migraine preventive medications, and better understanding of the use of other psychotropics.Keywords: headaches, triptans, migraine preventive therapy, comorbidity, psychotropicsMuzina DJChen WBowlin SJDove Medical PressarticleNeurosciences. Biological psychiatry. NeuropsychiatryRC321-571Neurology. Diseases of the nervous systemRC346-429ENNeuropsychiatric Disease and Treatment, Vol 2011, Iss Issue 1, Pp 663-672 (2011)
institution	DOAJ
collection	DOAJ
language	EN
topic	Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
spellingShingle	Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429 Muzina DJ Chen W Bowlin SJ A large pharmacy claims-based descriptive analysis of patients with migraine and associated pharmacologic treatment patterns
description	David J Muzina, William Chen, Steven J BowlinMedco Health Solutions Inc and Medco Research Institute, LLC, Franklin Lakes, NJ, USAPurpose: To investigate drug use, prescribing patterns, and comorbidities among patients with migraine in a large pharmacy claims database.Methods: 104,625 migraine subjects (identified according to the criteria in the International Classification of Diseases, Ninth Revision [ICD-9] for migraine or migraine-specific acute medication use) and an equal number of control patients were selected from a de-identified claims database; the prevalence of patients with migraine-specific claims was determined. Patient demographics, migraine-related medication use, other psychotropic medication use, and comorbidities over a 12-month period were compared between the migraine population and the control group and between migraine subgroups.Results: Of the study population, 3.5% had a migraine diagnosis according to the ICD-9 or received a migraine-specific acute medication. Compared with controls, migraine patients had significantly greater disease comorbidity and higher use of prescription nonsteroidal anti-inflammatory drugs and controlled painkillers; they were also more likely to receive medications used to prevent migraines and other nonmigraine psychotropic medications, such as anxiolytics and hypnotics. Among migraine patients, 66% received acute migraine-specific medication while only 20% received US Food and Drug Administration&ndash;approved migraine preventive therapy. Notably, one-third of high triptan users did not receive any kind of preventive medication. Multiple medical and psychiatric comorbidities were observed at higher rates among migraine sufferers. In addition to significantly higher utilization of antidepressants compared with controls, migraine patients also received significantly more other psychotropic drugs by a factor of 2:1.Conclusion: Acute migraine medications are commonly used and frequently dispensed at rates that raise concern of overuse; high use is often seen without any preventive medications. Furthermore, use of US Food and Drug Administration&ndash;approved preventive medications is low. Finally, patients with migraine are significantly more likely to receive other psychotropic medications. These findings suggest efforts to optimize the management of migraines could address appropriate use of triptans, increased and more effective use of migraine preventive medications, and better understanding of the use of other psychotropics.Keywords: headaches, triptans, migraine preventive therapy, comorbidity, psychotropics
format	article
author	Muzina DJ Chen W Bowlin SJ
author_facet	Muzina DJ Chen W Bowlin SJ
author_sort	Muzina DJ
title	A large pharmacy claims-based descriptive analysis of patients with migraine and associated pharmacologic treatment patterns
title_short	A large pharmacy claims-based descriptive analysis of patients with migraine and associated pharmacologic treatment patterns
title_full	A large pharmacy claims-based descriptive analysis of patients with migraine and associated pharmacologic treatment patterns
title_fullStr	A large pharmacy claims-based descriptive analysis of patients with migraine and associated pharmacologic treatment patterns
title_full_unstemmed	A large pharmacy claims-based descriptive analysis of patients with migraine and associated pharmacologic treatment patterns
title_sort	large pharmacy claims-based descriptive analysis of patients with migraine and associated pharmacologic treatment patterns
publisher	Dove Medical Press
publishDate	2011
url	https://doaj.org/article/a54c52379da94ed3b3ab73c79ca3db64
work_keys_str_mv	AT muzinadj alargepharmacyclaimsbaseddescriptiveanalysisofpatientswithmigraineandassociatedpharmacologictreatmentpatterns AT chenw alargepharmacyclaimsbaseddescriptiveanalysisofpatientswithmigraineandassociatedpharmacologictreatmentpatterns AT bowlinsj alargepharmacyclaimsbaseddescriptiveanalysisofpatientswithmigraineandassociatedpharmacologictreatmentpatterns AT muzinadj largepharmacyclaimsbaseddescriptiveanalysisofpatientswithmigraineandassociatedpharmacologictreatmentpatterns AT chenw largepharmacyclaimsbaseddescriptiveanalysisofpatientswithmigraineandassociatedpharmacologictreatmentpatterns AT bowlinsj largepharmacyclaimsbaseddescriptiveanalysisofpatientswithmigraineandassociatedpharmacologictreatmentpatterns
_version_	1718399652669161472

A large pharmacy claims-based descriptive analysis of patients with migraine and associated pharmacologic treatment patterns

Ejemplares similares